New Delhi | Jagran News Desk: The results of the keenly-awaited phase-I clinical trial of the purported COVID-19 vaccine formulated by the University of Oxford are likely to be released on Monday. The conclusions of the trial will be published in The Lancet, a weekly peer-reviewed medical journal.

"We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release," the Spokesperson of the journal was quoted as saying by Reuters. With the COVID-19 infection turning out to be a defining global health crisis, the medical fraternity is expecting news about the optimistic future of this fight against the novel coronavirus

Earlier, various media reports suggested that the team of researchers at Oxford have discovered a vaccine that could offer ‘double protection’ against the novel coronavirus.

 

Developers of the vaccine, known as AZD1222, said earlier this month they were encouraged by the immune response they had seen in trials so far and were expecting to publish Phase 1 data by the end of July.

The Oxford vaccine candidate, AZD1222 COVID-19 vaccine, formerly called ChAdOx1 nCoV-19, is currently undergoing its large-scale phase-III trials, after a series of preclinical and clinical successes in the trials earlier.
Oxford has tied up with Pune’s SII for vaccine production. Pune-based Serum Institute of India is world’s biggest vaccine-maker that produces over 1.5 billion doses of different vaccines every year.

 

SII has exclusively partnered with Oxford-Astrazeneca for the production of vaccine en masse, and SII’s CEO Adar Poonawala said that it would initiate the human trials of Oxford-Astrazeneca vaccine candidate from next month onward in India. According to Poonawala, confirmed vaccine success is still six months away from now. “We do not want to rush anything. We want to emphasis on safety and efficacy... and once we are confident of good and safe vaccine, we will announce but that is still six months away from now,” Adar told news agency PTI.

Posted By: